ストックスクリーナーアプリを入手
15.35
5.60%
-0.91
アフターアワーズ：
15.39
0.04
+0.26%
前日終値:
$16.26
開ける：
$15.69
24時間の取引高:
7,405
Relative Volume:
0.36
時価総額：
$42.48M
収益：
$5.02M
当期純損益:
$-18.31M
株価収益率:
-3.3885
EPS:
-4.53
ネットキャッシュフロー:
$-23.40M
1週間 パフォーマンス:
-11.37%
1か月 パフォーマンス:
-0.26%
6か月 パフォーマンス:
+7.27%
1年 パフォーマンス:
-39.04%
1日の値動き範囲:
$15.12
$16.26
1週間の範囲:
$15.12
$17.50
52週間の値動き範囲:
$12.12
$29.19
Vtv Therapeutics Inc Stock (VTVT) Company Profile
VTVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
15.35 | 42.48M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-05-30 | 開始されました | H.C. Wainwright | Buy |
| 2018-04-10 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | 開始されました | Northland Capital | Outperform |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2015-09-04 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-24 | 開始されました | Piper Jaffray | Overweight |
| 2015-08-24 | 開始されました | Stifel | Buy |
すべてを表示
Vtv Therapeutics Inc (VTVT) 最新ニュース
(VTVT) Trading Advice - news.stocktradersdaily.com
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World
(VTVT) Trading Signals - news.stocktradersdaily.com
vTv Therapeutics Inc Reports Q4 2024 EPS of -$0.55, Beating Esti - GuruFocus.com
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Nasdaq
VTv Therapeutics: Q4 Earnings Snapshot - CTPost
VTv Therapeutics: Q4 Earnings Snapshot -March 20, 2025 at 06:02 pm EDT - Marketscreener.com
vTv Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M - StockTitan
vTv Therapeutics Inc. (VTVT) reports earnings - Quartz
Why Celsius Holdings Stock Popped This Week - The Globe and Mail
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 13.6% - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Biotech Alert: Searches spiking for these stocks today - TipRanks
StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT) - Defense World
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial - GuruFocus.com
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup - MarketScreener
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care -March 17, 2025 at 03:39 pm EDT - Marketscreener.com
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges - Stocks Telegraph
vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study - Seeking Alpha
vTv Therapeutics resumes phase 3 diabetes trial By Investing.com - Investing.com Australia
VTv Therapeutics Says FDA Lifted Clinical Hold On Cadisegliatin Program For Diabetes - Nasdaq
vTv Therapeutics stock surges on FDA update By Investing.com - Investing.com Canada
Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell - Marketscreener.com
vTv Therapeutics stock surges on FDA update - Investing.com
vTv Therapeutics resumes phase 3 diabetes trial - Investing.com
vTv Therapeutics Announces Resumption of CATT1 Phase 3 Trial for Cadisegliatin as Potential First Oral Adjunct Therapy for Type 1 Diabetes - Nasdaq
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - The Manila Times
FDA Green Light: vTv's Revolutionary Oral Diabetes Drug Back on Track with Faster Timeline - StockTitan
3 Quality Compounders on Our Buy List - The Globe and Mail
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
vTv Therapeutics (VTVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
Long Term Trading Analysis for (VTVT) - Stock Traders Daily
vTv Therapeutics CFO to Resign in March By Investing.com - Investing.com Canada
vTv Therapeutics CFO to Resign in March - Investing.com
vTv Therapeutics CFO Steven Tuch to Resign - TipRanks
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
Vtv Therapeutics Inc (VTVT) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
大文字化:
|
ボリューム (24 時間):